"Insulin Glargine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.
Descriptor ID |
D000069036
|
MeSH Number(s) |
D06.472.699.587.200.300.100 D12.644.548.586.200.300.100
|
Concept/Terms |
Insulin Glargine- Insulin Glargine
- Glargine, Insulin
- A21-Gly-B31-Arg-B32-Arg-insulin
- A21 Gly B31 Arg B32 Arg insulin
- Insulin, Glycyl(A21)-Arginyl(B31,B32)
- Glargine
- Insulin, Gly(A21)-Arg(B31,B32)
Lantus- Lantus
- Lantus Solostar
- Solostar, Lantus
HOE 901- HOE 901
- 901, HOE
- HOE-901
- HOE901
|
Below are MeSH descriptors whose meaning is more general than "Insulin Glargine".
Below are MeSH descriptors whose meaning is more specific than "Insulin Glargine".
This graph shows the total number of publications written about "Insulin Glargine" by people in this website by year, and whether "Insulin Glargine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2012 | 0 | 2 | 2 |
2017 | 0 | 1 | 1 |
2019 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin Glargine" by people in Profiles.
-
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022 09 22; 387(12):1063-1074.
-
Self-Monitoring of Blood Glucose in Youth-Onset Type 2 Diabetes: Results From the TODAY Study. Diabetes Care. 2019 05; 42(5):903-909.
-
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017 07; 40(7):951-957.
-
Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: a pilot study. Acad Emerg Med. 2015 Jun; 22(6):657-62.
-
Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014 Jun; 16(6):483-91.
-
Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014 Mar; 16(3):193-205.
-
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012 Jun 15; 11(12):2314-26.
-
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62.
-
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012 Apr 21; 379(9825):1498-507.
-
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab. 2007 Jan; 9(1):103-13.